Latest Postherpetic neuralgia Stories

NEWARK, Calif., May 16, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York City. The presentation at the UBS conference is scheduled for 10 am EDT (7 am PDT) on Tuesday, May 21, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...

NEWARK, Calif., May 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2013 financial results after the market closes on Wednesday, May 8, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

CAMBRIDGE, England, April 23, 2013 /PRNewswire/ -- Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd. The trial is a randomised...

Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster, but uptake in the US is low A vaccine to prevent shingles may reduce by half the occurrence of this painful skin and nerve infection in older people (aged over 65 years) and may also reduce the rate of a painful complication of shingles, post-herpetic neuralgia, but has a very low uptake (only 4%) in older adults in the United States, according to a study by UK and US researchers published in...

Greater Reduction in Pain Intensity is One of the Greatest Unmet Needs in Postherpetic Neuralgia, According to a New Report from Decision Resources BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that reduction in pain intensity is one of the attributes that most influences their decisions regarding prescribing...

Thousand oaks based pain management center is expanding services to include advanced diagnostic imaging. Thousand Oaks, California (PRWEB) March 17, 2013 Comprehensive Pain Management Center (CPMC) in Thousand Oaks, California has been treating patients for moderate to severe pain since 2012. Beginning April 1st, 2013 CPMC will include advanced diagnostic imaging services on site. Dr. Lin and the Comprehensive Pain Management Center have recently acquired a GE 1.5 Tesla 450-Watt, Open...

NEWARK, Calif., March 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Roth Capital Partners 25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California. The presentation at the Roth conference is scheduled for 11:30 am PDT (2:30 pm EDT) on Tuesday March 19, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com....

NEWARK, Calif., Feb. 26, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston. The presentation at the Cowen conference is scheduled for 10:00 am EST (7:00 am PST) on Tuesday, March 5, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A...

NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2012 financial results after the market closes on Wednesday, February 20, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be...

NEWARK, Calif., Dec. 26, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that its lawsuits against two filers of Abbreviated New Drug Applications (ANDAs) for Gralise(®) (gabapentin) have been dismissed. Watson Laboratories has withdrawn its Gralise ANDA. Par Pharmaceutical has amended its Gralise ANDA and is no longer seeking approval of the ANDA prior to the expiration of Depomed's patents listed for Gralise in the FDA publication commonly known as the Orange...